Presbycusis

Sensorion Reports Full-Year 2023 Financial Results and Business Update

Retrieved on: 
목요일, 3월 14, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bioreactor, Malignancy, Cell, Chemistry, Patient, Orphan, Good manufacturing practice, Health care, CMC, G&A, Molecular biology, Quality of life, European Medicines Agency, Science, Clinical trial, Cisplatin, Therapy, Hertz, Neoplasm, CIO, Congress, Huber loss, Partnership, Ageing, EMA, Hearing loss, GMP, Cochlea, Biochemistry, Safety, Language, Perilymph, G7, Medication, Control, AAV, PTA, IHC, Pasteur Institute, CDMO, Communication, Genetics, Research, KOL, Ear, POC, FDA, Ototoxicity, GJB2, ABR, CTA, ANSM, Audiogram, Platinum, Investment company, Congenital hearing loss, Pathology, Presbycusis, Hearing, Pharmaceutical industry

Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.

Key Points: 
  • Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, today reports full-year 2023 financial results and business update.
  • Nawal Ouzren, Chief Executive Officer of Sensorion, said: “Over the past months, Sensorion has successfully achieved all the major milestones on its roadmap.
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV SENS-501 clinical batches at 200L scale.
  • On April 6, 2023, Sensorion announced the candidate selection for GJB2-GT during its gene therapy focused R&D Day.

New Study Finds Hearing Aids May Counter Cognitive Decline

Retrieved on: 
목요일, 1월 25, 2024
Ageing, Speech, Noise, Patient, Dementia, Thought, Hearing loss, Music, Risk, Kool-Aid, Audiology, Presbycusis, Quality of life, Hearing, Brain, Prevalence, Dentistry

PORT WASHINGTON, N.Y., Jan. 25, 2024 /PRNewswire/ -- A 2023 randomized trial known as ACHIEVE (Aging and Cognitive Health Evaluation in Elders) published in the scientific journal The Lancet, confirms what audiologists have long suspected but never had proof for. The ACHIEVE study found that, among older adults who have hearing loss combined with a higher risk of dementia, those who used hearing aids over a three-year period experienced 48% less cognitive change.

Key Points: 
  • The ACHIEVE study found that, among older adults who have hearing loss combined with a higher risk of dementia, those who used hearing aids over a three-year period experienced 48% less cognitive change.
  • "The ACHIEVE study is so significant and so huge in the treatment of hearing loss because, before this time, we just hypothesized that there was a relationship between treating hearing loss and cognitive decline," said Sapodin, an audiologist with the Long Island, N.Y.-based practice I Love Hearing.
  • "Now, we know for certain that hearing aids can slow cognitive decline in people with hearing loss who are at high risk for dementia."
  • Sapodin added that comprehensive hearing care from a professional audiologist is the best way to prevent and counter hearing loss and, thereby, cognitive decline.

Sensorion Reports 2023 First Half Results

Retrieved on: 
수요일, 9월 20, 2023
Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Genetics, Clinical Trials, Other Health, GMP, US Foods, Ear, PTA, European Medicines Agency, Huber loss, G&A, Malignancy, Patient, Institut Pasteur Korea, R, Cisplatin, POC, Pasteur Institute, Good manufacturing practice, Hearing loss, Congenital hearing loss, Cochlear Limited, IHC, Bioreactor, Perilymph, EMA, Platinum, Ototoxicity, HIV disease progression rates, Hearing, CIO, FDA, IND, Health care, Cochlea, Cell, AAV, GJB2, Presbycusis, Audiogram, Hertz, ANSM, KOL, Partnership, Neoplasm, Concept, Clinical trial, Quality of life, CTA, Medication, CDMO, Orphan, Pharmaceutical industry, Dentistry, Vaccine, Medical device, Cryptocurrency, Rare-earth element

In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV OTOF-GT batches at 200L clinical scale.

Key Points: 
  • In the first half of 2023, Sensorion achieved a major development milestone by completing the preclinical package, and successfully producing the GMP dual AAV OTOF-GT batches at 200L clinical scale.
  • In April 2023, Sensorion announced the candidate selection for GJB2-GT during its R&D Day focusing on gene therapy.
  • The first patient was enrolled in December 2022 and Sensorion anticipates the publication of the preliminary results in H2 2023.
  • The annual accounts on June 30, 2023, drawn up according to IFRS standards and approved by the Board of Directors on September 18, 2023.

Sensorion Reports 2022 First Half Results

Retrieved on: 
목요일, 9월 22, 2022
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Clinical Trials, Adult, Presbycusis, Ototoxicity, POC, Platinum, CMC, Cisplatin, GLP, ODD, AAV, COMP, Control, FDA, Cochlea, Research, CIO, European Medicines Agency, GJB2, Thermo Fisher Scientific, European Commission, CTA, Company, Treasury, G7, Hearing loss, Perilymph, Huber loss, Partnership, Cancer, Chemistry, Patient, Clinical trial, CEO, The Association, Royal IHC, CDMO, Solution, G&A, Pasteur Institute, Committee, Association, Mali, Animal, EMA, OTOF, Association for Research in Otolaryngology, Pharmaceutical industry, Medical device, Dentistry, Vaccine, Fine chemical, Otorhinolaryngology

Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its half-year results as of June 30, 2022, alongside its outlook for the remainder of 2022.

Key Points: 
  • Sensorion (FR0012596468 ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces its half-year results as of June 30, 2022, alongside its outlook for the remainder of 2022.
  • Nawal Ouzren, CEO of Sensorion, said: Sensorion has made good progress across our pipeline of small molecule and gene therapy programs in the first half of this year.
  • In late 2021, Sensorion filed a proof-of-concept clinical trial application in CIO to evaluate the potential of SENS-401 treatment.
  • Following further analysis of the AUDIBLE-S study earlier in 2022, Sensorion has adapted the NOTOXIS trial design to focus SENS-401 in the prevention arm only.

GrandPad releases tips for picking the perfect tech gift for seniors

Retrieved on: 
화요일, 11월 23, 2021
Skin, Caregiver, Ageing, Anxiety, CEO, Technology, Nursing, Music, Cognitive deficit, Memory, Presbycusis, Binary relation, Cognition, COVID-19, Wi-Fi, Adult, Tablet, Visual impairment, Arthritis, Smartphone, Friends, Severe cognitive impairment, Internet, Hearing loss, Online shopping, Management, Mobile phone

Look for devices, like GrandPad, that come with built-in cellular connectivity and free data service.

Key Points: 
  • Look for devices, like GrandPad, that come with built-in cellular connectivity and free data service.
  • "That's why we built GrandPad based on the insights and direction of those whom we lovingly call super seniors those individuals who are over the age of 75.
  • GrandPad is currently being used to connect more than 1.3 million people including seniors, family members, friends, and caregivers in more than 120 countries worldwide.
  • GrandPad offers the following features that can help seniors and families stay connected in a safe and simple way:
    Enables pre-loaded "trusted circle" of family contacts, photos, and apps

Sensorion And Hearing Care Leader Sonova Sign Strategic Research Collaboration

Retrieved on: 
수요일, 9월 15, 2021
Biotechnology, Pharmaceutical, Health, Medical Devices, People, Risk, Prevalence, Workforce, Knowledge, Association, Biomarker, Usher syndrome, Incidence, Mutation, Hearing loss, CEO, Hear the World Foundation, Bionics, Deafness, Trial of the century, Breast implant, CHF, Natural history study, SWX, Kool-Aid, Patient, Gene, Company, Group, Genetics, Disease, Disease management, Presbycusis, GJB2, Industry, Letter, Therapy, Communication, Solution, NHS, Population, Diagnosis, Life, Hearing, Unitron, Dentistry, Pharmaceutical industry, Natural History Study (NHS), Sensorion, Sonova, NATURAL HISTORY STUDY (NHS), SENSORION, SONOVA

We are very pleased to be working closely with Sonova in a collaboration to investigate inherited components of hearing loss, said Nawal Ouzren, CEO of Sensorion.

Key Points: 
  • We are very pleased to be working closely with Sonova in a collaboration to investigate inherited components of hearing loss, said Nawal Ouzren, CEO of Sensorion.
  • We believe that together with Sonova, we are driving future standards of hearing loss diagnosis and of therapy.
  • The aim of this joint project is to explore synergies between two approaches of hearing health care, traditional hearing care and emerging bio-pharmaceutical approaches which we believe will be largely complementary.
  • Pursuing a unique vertically integrated business strategy, the Group operates through three core businesses Hearing Instruments, Audiological Care and Cochlear Implants along the entire value chain of the hearing care market.